Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm presently has a $0.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 1.35% from the company’s current price.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
Several other research analysts have also recently issued reports on the stock. B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 27th. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 27th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, Roth Capital restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Five investment analysts have rated the stock with a buy rating, Actinium Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $3.75.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.